Fatty Liver Clinical Trials

Medicine trials for MASH with scarring. The largest group. These test whether a drug reduces inflammation and scarring in people whose fatty liver has progressed to fibrosis, usually stages F2 to F3, and increasingly whether it prevents cirrhosis and its complications over several years. Several are Phase 3, meaning the last stage before a company can ask the FDA for approval, and they include the GLP-1 class, FGF21 based medicines, and other new mechanisms.

Trials for compensated cirrhosis. A newer and smaller category for people whose scarring has reached cirrhosis but whose liver still works. Until recently almost no studies enrolled this group; now several do, because it is where the stakes are highest.

Weight and metabolic studies. Because fatty liver is a metabolic disease, many trials test weight loss medicines, metabolic surgery, or the biology linking obesity and liver fat. Some enroll people with elevated liver fat and excess weight before any scarring has appeared.

Diagnosis and imaging studies. Fatty liver is hard to stage without a biopsy, so a lot of research aims at better noninvasive tests: ultrasound and MRI methods that measure fat, blood biomarkers, and ways to spot scarring earlier. These often need no medicine change at all and welcome people at any stage.

Diet, meal timing, and lifestyle studies. Trials test specific eating patterns, time restricted eating, supplements, and exercise programs. Most enroll people with early disease, where lifestyle change alone can still reverse the fat.

Registries and natural history studies. These follow people over years to understand who progresses and why. No treatment is given, but they are where risk scores like FIB-4 came from, and they usually have the widest eligibility.

Almost every fatty liver study sorts people by stage, so the first thing to know is how much scarring you have. Medicine trials usually require confirmed MASH with fibrosis, shown by a FibroScan reading (often 8 to 20 kPa depending on the study), an ELF blood test, or a biopsy, plus a certain amount of liver fat on imaging. Many require a BMI of 25 or higher and exclude other liver diseases such as hepatitis B or C, heavy alcohol use, and autoimmune liver disease. Type 2 diabetes is usually fine if it is reasonably controlled; type 1 is often excluded. Studies commonly ask that your weight has been stable for the last few months, because rapid weight change on its own alters the liver. Diagnosis, imaging, and lifestyle studies often have much wider doors, including people with fat only, teenagers in pediatric studies, and people who simply want to be followed over time. Eligibility always varies by study.

Fatty liver disease is described by two things: whether there is inflammation, and how much scarring has formed.

Simple fatty liver (steatosis). Fat in the liver, no inflammation, no scarring. The most common stage, and the one that responds to weight loss within months. Lifestyle and diagnosis studies enroll here.

MASH (steatohepatitis). Fat plus inflammation. The liver is being irritated, and scarring may begin. Some medicine trials enroll early MASH with little or no fibrosis.

Fibrosis, stages F1 to F3. Scar tissue is forming. F1 is mild, F2 moderate, F3 advanced. On a FibroScan, F2 to F3 roughly corresponds to 8 to 15 kPa. This is where both approved medicines work and where most Phase 3 trials recruit.

Cirrhosis, stage F4. Scarring throughout the liver, usually above 15 kPa. Compensated cirrhosis means the liver still functions; decompensated means complications like fluid in the belly or bleeding veins have appeared. Compensated cirrhosis has its own trials; decompensated disease is usually excluded from them and studied separately.

Study titles name the stage they want, usually as "MASH with fibrosis," "F2 to F3," or "compensated cirrhosis." Knowing your FibroScan number or FIB-4 score tells you at a glance which studies fit. If you have never had either test, ask your doctor; it is the single most useful step before applying to anything.

Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.

Curious whether clinical trials pay participants? Here's how compensation actually works.

How Much do Clinical Trials Pay? Everything You Need to Know About Getting Paid For Clinical Trials

Enrolling in a fatty liver study through our platform takes about 5 minutes. Here is how it works:

Identify your trial. Use the search bar or filters. Study titles in this field are unusually specific about stage: "MASH with fibrosis," "compensated cirrhosis," or "elevated liver fat and obesity." If you know your stage, you can rule most studies in or out from the title alone. If you do not, start with imaging and lifestyle studies, which tend to have the widest eligibility.

Select your preferred location. Enter your city or state in the filter on the left. Phase 3 medicine trials run at hepatology and research centers and involve repeat visits, scans, and sometimes a biopsy, so distance matters. Diet, imaging, and registry studies are often closer to home.

Explore study details. Click "Learn More" for goals, procedures, and eligibility, including which FibroScan or ELF values are required, whether a liver biopsy is part of screening, which other liver conditions are excluded, and how many visits are scheduled.

Complete the health profile. Click "Get started" to begin the 5-step application. Have three things ready: your most recent FibroScan or FIB-4 result if you have one, your height and weight, and whether you have diabetes and your latest A1c. Those answers decide eligibility for most fatty liver studies. If you have only been told "fatty liver" on an ultrasound, say so; many studies confirm stage at a screening visit.

Submit the application. A clinical trial coordinator reviews it and contacts you about whether you may qualify. Nothing is decided until you have gone through informed consent, and participation is voluntary at every step.